In the city of Copenhagen, Pluslife is showcasing its newest point-of-care diagnostic innovations at the 33rd ECCMID Congress. Pluslife’s product demonstration is held in Booth No. B5-11 from Apr 15 to 18 and the latest developed POC Molecular Analyzer - Pluslife Dock Pro 8, test cards of GBS, Strep A, TV, and HPV are available for inquiries.

Pluslife's POC Molecular analyzer Mini Dock and Dock Pro 8 based on the self-developed RHAM methodology drew the attention of many experts at the congress. The two analyzers are highly maneuverable and capable of providing rapid and reliable diagnostic test results in 7 to 35 minutes for various applications. In combination with a broad test menu, diagnostic solutions for FLU, GBS, HPV, and others are offered to enable medical providers to streamline their processes and efficiently differentiate medical admissions.

A major focus of ECCMID’s symposiums is reducing the risk of sexually transmitted infections, and combating STIs is also a significant part of Pluslife's mission. During the exhibition, Pluslife's team shared their experiences of using the GBS, TV, CT/NG/UU Test Cards in community-based settings. Pluslife test performances are clinically proven and comparable to lab PCR tests. In addition, they can be transported and stored without a cold chain, which can significantly reduce costs. Thus, a number of NGOs and governments have approached Pluslife to inquire about a more cost-effective way to enhance the performance of healthcare facilities.

ECCMID provides opportunities for industry experts and colleagues to create synergy in solving problems of infectious diseases. Pluslife is pleased to share its latest innovations in Molecular POCT as part of the ECCMID Congress. Pluslife's next exhibition will be at Euromedlab 2023 in Rome.